LB Pharmaceuticals Taps Intra-Cellular Therapies Veteran as CMO Ahead of Key Trial Readout
Event summary
- LB Pharmaceuticals appoints Susan G. Kozauer, M.D. as Chief Medical Officer effective September 15, 2026.
- Dr. Kozauer brings 20+ years of neuropsychiatric drug development experience, including leadership roles at Intra-Cellular Therapies and Centessa Pharmaceuticals.
- Appointment comes ahead of Phase 3 NOVA-2 trial results for schizophrenia treatment LB-102, expected in first half of 2027.
- LB-102 is positioned as a potential first benzamide antipsychotic for neuropsychiatric disorders in the U.S.
The big picture
The appointment of a seasoned neuropsychiatric drug developer as LB Pharmaceuticals prepares for its pivotal trial readout underscores the strategic importance of clinical execution in the competitive antipsychotic market. With LB-102 potentially offering a differentiated benzamide profile, the company is positioning itself to challenge established treatments if the Phase 3 data proves positive. The move comes as major pharma players like Johnson & Johnson and Eli Lilly continue to invest heavily in neuropsychiatric indications.
What we're watching
- Trial Timing
- Whether LB Pharmaceuticals can maintain its aggressive timeline for NOVA-2 results given the complexity of neuropsychiatric indications.
- Regulatory Pathway
- How Dr. Kozauer's experience with FDA approvals will shape LB-102's regulatory strategy across multiple indications.
- Pipeline Expansion
- The pace at which LB Pharmaceuticals can leverage Kozauer's expertise to expand LB-102 into additional neuropsychiatric disorders.